<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044534</url>
  </required_header>
  <id_info>
    <org_study_id>GY0005</org_study_id>
    <nct_id>NCT04044534</nct_id>
  </id_info>
  <brief_title>Intranasal Insulin for Posttraumatic Stress Disorder</brief_title>
  <official_title>Intranasal Insulin for Treating Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Connecticut Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current proposal aims to study the pharmacotherapeutic effects of intranasal insulin on
      PTSD symptoms and inhibition of amygdala hyperactivation in subjects with PTSD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-traumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)</measure>
    <time_frame>1 week</time_frame>
    <description>The five-point CAPS-5 consists of 20 PTSD symptoms rated on a 0-4 scale (total range: 0-80) as follows: (1) 5 Intrusion symptoms (0-20), (2) 2 Avoidance symptoms (0-8), (3) 7 Cognitions and mood symptoms (0-28), and (4) 6 Arousal and reactivity symptoms (0-24). Higher scores represent a worse outcome (i.e., more PTSD symptoms).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Intranasal insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal insulin</intervention_name>
    <description>Subjects in this arm will receive intranasal insulin (80 IU per day).</description>
    <arm_group_label>Intranasal insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm will receive placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 21-65 years old

          -  Current PTSD

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Unstable medical condition, clinically determined by a physician

          -  Diabetes requiring insulin or oral hypoglycemic agents

          -  Moderate-severe traumatic brain injury

          -  Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months

          -  Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3
             months

          -  Changes in doses of psychotropic medications in the past 4 weeks

          -  Initiation of individual therapy or counseling in the past 4 weeks

          -  Imminent suicidal or homicidal risk

          -  Contraindication to Insulin

          -  History of claustrophobia

          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal
             foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety
             screening questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gihyun Yoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gihyun Yoon, MD</last_name>
    <phone>(203) 932-5711</phone>
    <phone_ext>7421</phone_ext>
    <email>gihyun.yoon@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gihyun Yoon, MD</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>7421</phone_ext>
      <email>gihyun.yoon@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Connecticut Healthcare System</investigator_affiliation>
    <investigator_full_name>Gihyun Yoon, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intranasal insulin</keyword>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

